Biblio

Author Title Type [ Year(Desc)]
Filters: Author is Raffel, Simon  [Clear All Filters]
2015
Stockklausner C, Raffel S, Klermund J, Bandapalli OReddy, Beier F, Brümmendorf TH, Bürger F, Sauer SW, Hoffmann GF, Lorenz H, et al. A novel autosomal recessive TERT T1129P mutation in a dyskeratosis congenita family leads to cellular senescence and loss of CD34+ hematopoietic stem cells not reversible by mTOR-inhibition. Aging (Albany NY). 2015.
2016
Raffel S, Trumpp A. miR-126 Drives Quiescence and Self-Renewal in Leukemic Stem Cells. Cancer Cell. 2016;29(2):133-135.
2021
Saeed BR, Manta L, Raffel S, Pyl PTheodor, Buss EC, Wang W, Eckstein V, Jauch A, Trumpp A, Huber W, et al. Analysis of non-leukemic cellular subcompartments reconstructs clonal evolution of acute myeloid leukemia and identifies therapy-resistant pre-leukemic clones. Int J Cancer. 2021.
2022
Hernández-Malmierca P, Vonficht D, Schnell A, Uckelmann HJ, Bollhagen A, Mahmoud MAA, Landua S-L, van der Salm E, Trautmann CL, Raffel S, et al. Antigen presentation safeguards the integrity of the hematopoietic stem cell pool. Cell Stem Cell. 2022;29(5):760-775.e10.
Raffel S, Velten L, Haas S. Cellular hierarchies predict drug response in acute myeloid leukemia. Cancer Cell. 2022.
2023
Beneyto-Calabuig S, Merbach AKathrin, Kniffka J-A, Antes M, Szu-Tu C, Rohde C, Waclawiczek A, Stelmach P, Gräßle S, Pervan P, et al. Clonally resolved single-cell multi-omics identifies routes of cellular differentiation in acute myeloid leukemia. Cell Stem Cell. 2023.
Waclawiczek A, Leppa A-M, Renders S, Stumpf K, Reyneri C, Betz B, Janssen M, Shahswar R, Donato E, Karpova D, et al. Combinatorial BCL-2 family expression in Acute Myeloid Leukemia Stem Cells predicts clinical response to Azacitidine/Venetoclax. Cancer Discov. 2023.
Gökbuget N, Ihrig K, Stadler M, Stelljes M, Elmaagli A, Starck M, Raffel S, Stoltefuss A, Viardot A, Kreuzer K-A, et al. General condition and comorbidity of long-term survivors of adult acute lymphoblastic leukemia. Haematologica. 2023.
Stelljes M, Raffel S, Alakel N, Wäsch R, Kondakci M, Scholl S, Rank A, Hänel M, Spriewald B, Hanoun M, et al. Inotuzumab Ozogamicin as Induction Therapy for Patients Older Than 55 Years With Philadelphia Chromosome-Negative B-Precursor ALL. J Clin Oncol. 2023:JCO2300546.